Kaplan Andrew T.
Insider CIK 1752059 · SGRY Director, 10% owner · KLRA Director, 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| KLRA Kailera Therapeutics, Inc. | C Conversion deriv | 2026-04-20 | 2026-04-20 | 17,857,143 | — | $0 | 0 | SEC↗ |
| KLRA Kailera Therapeutics, Inc. | C Conversion | 2026-04-20 | 2026-04-20 | 17,857,143 | — | $0 | 17,857,143 | SEC↗ |
| KLRA Kailera Therapeutics, Inc. | P Buy | 2026-04-20 | 2026-04-20 | 8,398,438 | $16.00 | $134.38M | 26,255,581 | SEC↗ |
| KLRA Kailera Therapeutics, Inc. | A Award deriv | 2026-04-16 | 2026-04-20 | 38,300 | — | $0 | 38,300 | SEC↗ |
| SGRY Surgery Partners, Inc. | S Sale | 2023-12-19 | 2023-12-21 | 7,826,870 | $33.44 | $261.73M | 50,421,379 | SEC↗ |
| SGRY Surgery Partners, Inc. | J Other | 2023-12-19 | 2023-12-21 | 474,407 | — | $0 | 49,946,972 | SEC↗ |